ESR1 and neoplasm: In ER+ BMET models, E2 bone-microenvironmental effects have often not been considered[19,21–26,39,40] and are rarely documented[18,20,28], while a role of tumor ERα signaling in driving tumor-associated osteolysis has not, to our knowledge, previously been studied.